RxDoctor Payments Data

Mark Hostettler, MD

Internal Medicine · Alliance, OHNPI 1265431753

Payments from drug & device makers

$8,971in general payments, 2019–2025

Across 686 payments — averaging $13.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$952
  • Pfizer$903
  • AstraZeneca$829
  • Amarin Pharma, Inc.$742
  • Lilly USA, LLC$694
  • Novo Nordisk$524
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$8,68297%
  • Education$651%
  • Other$2253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)75$952
Pfizer79$903
AstraZeneca50$829
Amarin Pharma, Inc.100$742
Lilly USA, LLC53$694
Novo Nordisk34$524
Johnson & Johnson35$498
Merck35$446
Takeda Pharmaceuticals U.S.A., Inc.23$310
GSK18$272
Boehringer Ingelheim16$242
Welch Allyn1$225
Novartis15$217
Amgen(2 entities)13$217
Antares Pharma, Inc.11$199
Biohaven Pharmaceutical Holding Company Ltd.21$151
Exact Sciences7$131
Biohaven Pharmaceuticals, Inc.19$127
Abbott7$110
Astellas Pharma US Inc6$94
E.r. Squibb & Sons, L.L.C.6$94
Amneal Pharmaceuticals LLC4$76
Sanofi-aventis U.S. LLC5$71
Axsome Therapeutics, Inc.4$68
Kowa Pharmaceuticals America, Inc.4$49
Genentech USA, Inc.3$46
Bayer3$45
Boston Scientific1$45
Phathom Pharmaceuticals, Inc.3$43
Halozyme Inc2$32
Mylan Specialty L.p.2$32
Lundbeck LLC2$31
Clarus Therapeutics Inc.2$30
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$29
Madrigal Pharmaceuticals1$26
Sunovion Pharmaceuticals Inc.2$26
Eisai Inc.2$24
Viatris Specialty LLC1$23
Pulmonx Corporation1$23
Hikma Pharmaceuticals USA1$21
Sumitomo Pharma America, Inc.1$20
Arbor Pharmaceuticals, Inc.1$20
Azurity Pharmaceuticals, Inc.1$20
Radius Health, Inc.1$19
Vivus LLC1$17
Supernus Pharmaceuticals, Inc.1$16
Grifols USA, LLC1$16
Esperion Therapeutics, Inc.1$15
Vivaquant Inc, Dba Rhythm Express1$15
Athena Bioscience, LLC1$15
Avanir Pharmaceuticals, Inc.1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$14
Shield Therapeutics Inc1$13
Echosens North America, Inc.1$12
Almatica Pharma LLC1$12
Sun Pharmaceutical Industries Inc.1$11
Inogen, Inc.1$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,971 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$93,132
Medicare patients
246
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin74$84,006
XareltoRivaroxaban69$72,040
EliquisApixaban97$69,576
OzempicSemaglutide31$44,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$26,884
Tresiba Flextouch U-200Insulin Degludec22$24,558
FarxigaDapagliflozin Propanediol11$19,524
JanuviaSitagliptin Phosphate17$17,132
MounjaroTirzepatide17$16,588
Tresiba Flextouch U-100Insulin Degludec20$12,618
SymbicortBudesonide/Formoterol Fumarate19$10,313
MyrbetriqMirabegron11$8,377
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,645
PaxlovidNirmatrelvir/Ritonavir26$5,768
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$5,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$242$84,00674 claims
PfizerEliquis, Paxlovid$903$75,344123 claims
Johnson & JohnsonXarelto$498$72,04069 claims
Novo NordiskOzempic$524$44,02131 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere, Bevespi Aerosphere$829$41,57753 claims
GSKTrelegy Ellipta, Breo Ellipta$272$32,06448 claims
MerckJanuvia$446$17,13217 claims
Lilly USA, LLCMounjaro$694$16,58817 claims
Astellas Pharma US IncMyrbetriq$94$8,37711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$76$3,533334 claims
AbbVieSynthroid$952$2,33246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Alliance

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →